DMCA / copyright notice
Last updated: 2026-05-28
GLPZoom respects the intellectual property rights of others. We respond to clear notices of alleged copyright infringement that comply with the Digital Millennium Copyright Act (DMCA), 17 U.S.C. §512. This page describes how to submit a notice, our designated agent, and the counter-notification procedure for content removed in error.
Designated agent for copyright claims
Designated Copyright Agent
GLPZoom Editorial Operations
Attn: DMCA Agent
Email: [email protected]
Postal address is provided to the U.S. Copyright Office DMCA Agent Directory and made available to claimants on written request, to reduce inbox spam from automated scrapers. Email is the fastest channel and is monitored daily.
How to file a DMCA notice
To be effective under the DMCA, your notice must include all of the following (17 U.S.C. §512(c)(3)(A)):
- A physical or electronic signature of the copyright owner or person authorized to act on their behalf.
- Identification of the copyrighted work claimed to be infringed (URL, title, registration number if applicable).
- Identification of the allegedly infringing material on our site, with enough detail to locate it: the full URL and the specific element (text passage, image, video).
- Your contact information: legal name, mailing address, telephone number, email address.
- A statement, under penalty of perjury, that you have a good-faith belief that the use is not authorized by the copyright owner, its agent, or the law.
- A statement, under penalty of perjury, that the information in the notice is accurate, and that you are authorized to act on behalf of the copyright owner.
Important: Section 512(f) of the DMCA imposes liability on any person who knowingly materially misrepresents that material is infringing. Frivolous, false, or harassing notices are rejected and may be reported to the U.S. Copyright Office.
Our response
Upon receipt of a compliant notice, we will:
- Within 1 business day: acknowledge receipt of the notice.
- Within 3 business days: review the notice, take appropriate action (remove or disable access to the material, or decline with reasoning), and notify the alleged infringer.
- Maintain a record of the notice and our action for compliance purposes.
Counter-notification
If your content has been removed and you believe the removal was in error or based on misidentification, you may file a counter-notice. A valid counter-notification (17 U.S.C. §512(g)(3)) must include:
- Your physical or electronic signature.
- Identification of the removed material and the location at which it appeared before removal.
- A statement, under penalty of perjury, that you have a good-faith belief that the material was removed as a result of mistake or misidentification.
- Your name, address, telephone number, and a statement consenting to the jurisdiction of the federal district court for the judicial district where your address is located, or if outside the U.S., the district where GLPZoom is located, and that you will accept service of process from the original complaining party.
Submit counter-notifications to [email protected]. If we determine the counter-notice is valid and receive no notice from the original complainant that they have filed suit within 10-14 business days, we will restore the material.
Repeat-infringer policy
Per 17 U.S.C. §512(i), we maintain a policy of terminating, in appropriate circumstances, the accounts of users (contributors, guest authors, comment posters) who are determined to be repeat infringers. “Repeat infringer” means a user against whom three or more unrelated, valid DMCA notices have been received within any 12-month window.
Trademark and right-of-publicity claims
DMCA covers copyright only. For trademark infringement claims, right-of-publicity claims, defamation claims, or other non-copyright IP concerns, contact [email protected]. We follow analogous notice-and-response procedures for these claims though they are not statutory under DMCA.
Editorial fair-use note
GLPZoom publishes editorial content about telehealth services, medications, and clinical evidence. We quote, summarize, and reference FDA prescribing information, peer-reviewed publications, and third-party content under principles of fair use (17 U.S.C. §107), including: short quotations with attribution, transformative commentary, comparison and review, and educational use. If you believe a specific use exceeds fair use, please send a DMCA notice rather than a public allegation, so we can evaluate and respond promptly.
Related: all legal documents, editorial policy, corrections policy.